Business
Marvel Biosciences Secures Alberta Innovates Funding to Support the Phase I Testing of MB-204
CALGARY, Alberta, March 30, 2026 (GLOBE NEWSWIRE) -- Marvel Biosciences Corp. (TSXV: MRVL | OTC: MBCOF), and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively “Marvel” or the “Company”), a drug discovery company developing novel therapeutics for autism spectrum disorder and related conditions, today announced it has secured non-dilutive funding from the Alberta Innovates CarE (AICE) market access program to support the Phase I testing of its lead compound, MB-204. The $600,000
About this update from Marvell Technology, Inc.
[{"type":"image","alt":"Marvel Biosciences Corp.","displaySize":"","headline":null,"caption":"Marvel Biosciences Corp.","className":"","disableSlideshowImg":false,"size":{"original":{"width":172,"height":56,"url":"https://media.zenfs.com/en/globenewswire.com/86351d65fc33f7ecb9ed9578b1c43a0a"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/P0thqX1aufdkag28lDRWIA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIxMDtoPTY4/https://media.zenfs.com/en/globenewswire.com/86351d65fc33f7ecb9ed9578b1c43a0a","width":172,"height":56}},"lazy":false},{"type":"text","content":"CALGARY, Alberta, March 30, 2026 (GLOBE NEWSWIRE) -- Marvel Biosciences Corp. (TSXV: MRVL | OTC: MBCOF), and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively “Marvel” or the “Company”), a drug discovery company developing novel therapeutics for autism spectrum disorder and related conditions, today announced it has secured non-dilutive funding from the Alberta Innovates CarE (AICE) market access program to support the Phase I testing of its lead compound, MB-204.","length":487,"tagName":"p"},{"type":"text","content":"The $600,000 AICE-funded project represents a significant contribution toward the overall cost of the Phase I clinical trial of MB-204 and supports the advancement of the program into human trials. The AICE program is highly competitive and subject to rigorous peer review, providing strong third-party validation of the scientific and commercial potential of MB-204.","length":367,"tagName":"p"},{"type":"text","content":"“On behalf of Marvel Biosciences, we are very grateful to Alberta Innovates for recognizing the importance and potential of MB-204 as a novel approach to treating autism spectrum disorders (ASD) and related conditions” commented CEO Rod Matheson. “This competitive, peer-reviewed funding reinforces growing confidence around MB-204, and its potential to address socio-behavioural symptoms through a differentiated mechanism.”","length":425,"tagName":"p"},{"type":"text","content":"In addition to this award, Marvel also recently received a grant from the National Research Council of Canada Industrial Research Assistance Program (NRC IRAP) for the development of a novel, small volume, liquid-based formulation of MB-204. This pediatric-friendly formulation is designed to improve patient compliance, particularly for individuals with difficulty swallowing (refer to press rele...